Actavis, Inc. to Host Fourth Quarter 2012 Earnings Conference Call and Webcast

Fri Feb 1, 2013 9:16am EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130201:nPnNY52685










PARSIPPANY, N.J., Feb. 1, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT),
announced today that it intends to release fourth quarter 2012 financial results
on  Tuesday, February 19, 2013, prior to the open of the U.S. financial markets.
 The Company will host a conference call and webcast at  8:30 a.m. Eastern Time 
on  Tuesday, February 19, 2013  to discuss its financial results.  The dial-in
number to access the call is US/Canada  (877) 251-7980, International (706)
643-1573, and the Conference ID is 94810189.

A taped replay of the conference call will also be available beginning
approximately two hours after the call's conclusion and will remain available
through 12:00  midnight Eastern Time  on  March 5, 2013.  The replay may be
accessed by dialing (855) 859-2056 and entering pass code 94810189.  From
international locations, the replay may be accessed by dialing (404) 537-3406
and entering the same pass code.  To access the webcast, go to Actavis' Investor
Relations Web site at  http://ir.actavis.com.  A replay of the webcast will also
be available.

About Actavis, Inc.
Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical
company focused on developing, manufacturing and distributing generic, brand and
biosimilar products.  The Company has global and U.S. headquarters in 
Parsippany, New Jersey, USA, and international headquarters in Zug, Switzerland.
  

Actavis is the world's third-largest generics prescription drug manufacturer. 
Operating as Actavis Pharma, the Company develops, manufactures and markets
generic, branded generic, legacy brands and Over-the-Counter (OTC) products in
more than 60 countries.  The Company is ranked in the top 3 in 12 global
markets, the top 5 in 16 global markets, and in the top 10 in 33 global markets.
  Actavis Pharma also develops and out-licenses generic pharmaceutical products
outside the U.S. through its Medis third-party business, the world's largest
generic pharmaceutical out-licensing business. Medis has more than 300 customers
globally, and offers a broad portfolio of more than 200 products.   

Actavis Specialty Brands is the Company's global branded specialty
pharmaceutical business, which develops and markets a portfolio of approximately
40 products principally in  the United States  and  Canada  that are focused in
the Urology and Women's Health therapeutic categories.  Actavis Specialty Brands
is committed to developing and marketing biosimilars products in Women's Health,
Oncology and other therapeutic categories, and currently has a portfolio of 5
biosimilar products in development.  

Actavis Global Operations has more than 30 manufacturing and distribution
facilities around the world, with a capacity of approximately 44 billion units
annually.  Actavis Global Operations also includes Anda, Inc., the
fourth-largest U.S. generic pharmaceutical product distributor in  the United
States.

For press release and other company information, visit Actavis' Web site at 
http://www.actavis.com.

CONTACTS:  
Investors:
Lisa DeFrancesco
(862) 261-7152



Media:
Charlie Mayr
(862) 261-8030

(Logo:  http://photos.prnewswire.com/prnh/20130124/NY47381LOGO  )

SOURCE  Actavis, Inc.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.